A chemist a UAlbany and his son are looking to make a major breakthrough in the world of Alzheimer's prevention. They believe ...

Leqembi’s rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and ...

AC Immune said its partner Life Molecular Imaging received fast-track designation from the U.S. Food and Drug Administration ... conditions: Alzheimer's disease, progressive supranuclear palsy ...

The FDA approved the drug based off a late-stage clinical ... “It’s very important to recognize those early symptoms of Alzheimer’s and to get diagnosed early so these treatments are an ...

The designation is granted for its use in Alzheimer’s disease ... degeneration. The FDA's Fast Track program expedites the development and review of drugs that treat serious conditions and ...

Digital twins are giving a shot in the arm to the costly, failure-prone drug-making process. But enormous data needs and ...

SO YOU CAN IMAGINE STUDIES ARE ALSO GOING TO BE DONE IN ALZHEIMER’S DISEASE. ADDICTION ... with type 2 diabetes.In order for the drug to get FDA approval for use in these people with heart ...

The designation is granted for its use in Alzheimer’s disease, progressive supranuclear palsy, and corticobasal degeneration. The FDA's Fast Track program expedites the development and review of drugs ...